EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Advances in and Clinical Experience with Subcutaneous Infusion Pump Therapy for Pulmonary Arterial Hypertension

Valerie LaRoy, Eric Roberts, Jennalyn Mayeux, Natalie Patzlaff, Reem Ismail, Kari Roberts, Lori Reed, Traci Stewart, Mary Whittenhall, Melisa Wilson iD

Advances in Therapy · 2026

DOI: 10.1007/s12325-025-03468-1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advances in Therapy, 2026. Verfasst von Valerie LaRoy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary Hypertension Program, Advocate Christ Medical Center, 4440 West 95th Street, Oak Lawn, IL, USA. Hauptthemen laut MEDLINE: Antihypertensive Agents, Epoprostenol, Hypertension, Pulmonary, Pulmonary Arterial Hypertension. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: United Therapeutics Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary arterial hypertension (PAH) is characterized by progressive pulmonary vascular remodeling and a deficiency of endogenous prostacyclin, a potent vasodilator with antiproliferative effects. Prostacyclin analogues (PCAs) target this deficiency and are integral to the PAH treatment algorithm. Parenteral PCA therapy is recommended for patients at intermediate-high and high risk, and early initiation-particularly in combination regimens-is associated with improved survival in real-world and post hoc analyses.The 2002 approval of the parenteral PCA treprostinil (Remodulin®) marked a significant advancement in PCA therapy. Compared with epoprostenol, treprostinil offers greater chemical stability at room temperature and a longer half-life, enabling subcutaneous (SC) infusion and minimizing the complications and challenges associated with intravenous delivery. Despite robust evidence demonstrating its benefits on morbidity and mortality and risk-based guideline recommendations, parenteral PCA therapy remains underutilized. Contributing factors include concerns about the complexity and perceived burden of pump-based delivery systems.Here we review the place for parenteral prostacyclin in PAH therapy, and the evolution of SC PCA pumps over time, with a focus on recent enhancements intended to overcome practical limitations of older devices and thereby improve usability. Key features such as simplified cassette filling, automated priming, a larger and more intuitive touchscreen remote, and expanded flow rate options aim to reduce the perceived challenges of SC therapy and support broader adoption among patients and prescribers. The article also provides perspectives and practical guidance from experienced practitioners on the initiation and maintenance of SC PCA therapy, emphasizing how improvements in pump technology can help overcome barriers to use. Addressing these challenges through improved design, education, and support may help bridge the gap between evidence-based recommendations and real-world practice.Graphical abstract available for this article.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antihypertensive AgentsEpoprostenolHypertension, PulmonaryPulmonary Arterial HypertensionHumansInfusion PumpsInfusions, Subcutaneous

Stichwörter der Autor:innen

Prostacyclin analoguePulmonary arterial hypertensionRemunityPROTreprostinil

Substanzen

Antihypertensive AgentsEpoprostenoltreprostinil

Autor:innen und Institutionen

  • Pulmonary Hypertension Program, Advocate Christ Medical Center, 4440 West 95th Street, Oak Lawn, IL, USA.
  • Advanced Heart Failure and Transplant Cardiology, Aurora Health Care, 2900 West Oklahoma Avenue, Milwaukee, WI, USA.
  • Pulmonary Division, University of Utah, 1280 Stringham Avenue, Salt Lake City, UT, USA.
  • Global Medical Affairs, United Therapeutics, 55 TW Alexander Drive, Research Triangle Park, Durham, NC, USA.
  • Pulmonology, Piedmont Healthcare, 275 Collier Road Northwest, Atlanta, GA, USA.
  • Advanced Heart and Lung Program, University of Iowa, 200 Hawkins Drive, Iowa City, IA, USA.

ORCID-Profile: Melisa Wilson

Förderung

  • United Therapeutics Corporation

Zitieren

APA

LaRoy, V., Roberts, E., Mayeux, J., Patzlaff, N., Ismail, R., Roberts, K., Reed, L., Stewart, T., Whittenhall, M., & Wilson, M. (2026). Advances in and Clinical Experience with Subcutaneous Infusion Pump Therapy for Pulmonary Arterial Hypertension. Advances in Therapy. https://doi.org/10.1007/s12325-025-03468-1

Vancouver

LaRoy V, Roberts E, Mayeux J, Patzlaff N, Ismail R, Roberts K, et al. Advances in and Clinical Experience with Subcutaneous Infusion Pump Therapy for Pulmonary Arterial Hypertension. Advances in Therapy. 2026. doi:10.1007/s12325-025-03468-1

BibTeX
@article{LaRoy2026,
  author = {LaRoy, Valerie and Roberts, Eric and Mayeux, Jennalyn and Patzlaff, Natalie and Ismail, Reem and Roberts, Kari and Reed, Lori and Stewart, Traci and Whittenhall, Mary and Wilson, Melisa},
  title = {Advances in and Clinical Experience with Subcutaneous Infusion Pump Therapy for Pulmonary Arterial Hypertension},
  journal = {Advances in Therapy},
  year = {2026},
  doi = {10.1007/s12325-025-03468-1}
}
Kostenlos starten →